According to the SEC Form 4 filings, Lorrain Daniel S., being in a position of
No biography is available at this moment.
Buys | $0 | 0 | 0 |
Sells | $1,162,624 | 15 | 100 |
| 2026-07-09 | Sale | Contineum Therapeutics, Inc. CTNM | Chief Scientific Officer | 25 <0.0001% | $16.00 | $400 | -8.67% | |
| 2026-07-01 | Sale | Contineum Therapeutics, Inc. CTNM | Chief Scientific Officer | 8,353 0.0232% | $15.84 | $132,290 | -6.63% | |
| 2026-06-30 | Sale | Contineum Therapeutics, Inc. CTNM | Chief Scientific Officer | 28,826 0.0754% | $16.04 | $462,288 | -12.75% | |
| 2026-06-01 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0109% | $13.16 | $54,862 | +5.73% | |
| 2026-05-01 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0122% | $13.12 | $54,694 | +4.47% | |
| 2026-04-06 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0112% | $13.43 | $56,014 | +0.37% | |
| 2026-03-02 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0112% | $15.01 | $62,585 | -12.39% | |
| 2026-02-25 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 3,824 0.0106% | $16.01 | $61,228 | -14.8% | |
| 2026-02-24 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,300 0.0118% | $16.03 | $68,936 | -15.57% | |
| 2026-02-19 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 100 0.0003% | $16.00 | $1,600 | -15.75% | |
| 2026-02-11 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 400 0.0011% | $16.00 | $6,400 | -11.34% | |
| 2026-02-03 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0112% | $14.94 | $62,305 | -10.91% | |
| 2026-02-03 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 3,000 0.008% | $14.82 | $44,469 | -10.91% | |
| 2026-01-05 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0149% | $10.44 | $43,543 | +35.3% | |
| 2025-12-23 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 4,170 0.0143% | $12.23 | $51,009 | +9.22% | |
| 2024-11-25 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 1,010 0.0042% | $16.02 | $16,177 | -49.38% | |
| 2024-11-18 | Sale | Contineum Therapeutics, Inc. Class A Common Stock CTNM | Chief Scientific Officer | 6,190 0.0264% | $16.38 | $101,421 | -50.88% |